NDA 211413 · Hq Spclt Pharma
Cefazolin Sodium
Cefazolin Sodium · Intravenous
Last checked: Nov 19, 2026Latest source record: Feb 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
May 8, 2023
Approved uses
2
Original approval plus efficacy supplements
Registered trials
207
37 Phase 3, 20 recruiting
FAERS reports
12,207
11,391 serious, 1,402 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 27, 2026.
Cefazolin for Injection is a cephalosporin antibacterial indicated for perioperative prophylaxis in adult patients (1.1). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection and other antibacterial drugs, Cefazolin for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria (1.2). 1.1 Perioperative Prophylaxis Cefazolin for Injection is indicated for perioperative prophylaxis in adult patients [see Dosage and Administration (2.1, 2.2, 2.3) . The perioperative use of Cefazolin for Injection is indicated in adult surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for Injection preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection and other antibacterial drugs, Cefazolin for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric...
Mechanism: Cefazolin is an antibacterial drug [see Microbiology (12.4)] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 13, 2026 Supplement 3 · Efficacy LetterLabel
- May 8, 2023 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
2 products under this application
- CEFAZOLIN SODIUM · CEFAZOLIN SODIUM EQ 3GM BASE/VIAL · POWDER, INTRAVENOUS · Prescription
- CEFAZOLIN SODIUM · CEFAZOLIN SODIUM EQ 2GM BASE/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cefazolin" as an intervention, any sponsor and status, largest first.
- Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over TrialPivotal-lookingNot yet recruiting
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT06567808 · 38,000 participants (planned) · Start Mar 1, 2026 · Primary completion Apr 30, 2028
Drug: Cefazolin; Vancomycin · For: Infection, Surgical Site
VA Office of Research and DevelopmentFederal agency
NCT02216227 · 23,005 participants · Start Apr 1, 2014 · Primary completion Feb 28, 2021
Drug: Mupirocin; Chlorhexidine gluconate and 3 more · For: Surgical Site Infection
Sites: Miami, Florida; Iowa City, Iowa; Baltimore, Maryland · 11 sites in all
- Prevention of Arrhythmia Device Infection Trial (PADIT)Pivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT01628666 · 12,814 participants · Start Dec 2012 · Primary completion Sep 8, 2017
Drug: Incremental; Conventional · For: Arrhythmia
Sites: Hamilton, Canada
- Duration of Cardiac Antimicrobial Prophylaxis Outcomes StudyPivotal-lookingRecruiting
Monash UniversityAcademic, hospital or other
NCT05447559 · 9,180 participants (planned) · Start Feb 7, 2023 · Primary completion Dec 2027
Drug: Cefazolin; Water for injection · For: Surgical Site Infection
Sites: Dallas, Texas; Sydney, Australia; Brisbane, Australia · 27 sites in all
- Staphylococcus Aureus Network Adaptive Platform TrialPivotal-lookingRecruiting
University of MelbourneAcademic, hospital or other
NCT05137119 · 8,000 participants (planned) · Start Feb 16, 2022 · Primary completion Dec 1, 2028
Drug: Cefazolin; Penicillin and 2 more · For: Staphylococcus Aureus Bacteremia
Sites: Houston, Texas; Garran, Australia; Blacktown, Australia · 161 sites in all
- Prevention of Infections in Cardiac SurgeryPivotal-lookingTerminated
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT02285140 · 5,989 participants · Start Apr 2015 · Primary completion Mar 10, 2025
Drug: Cefazolin; Vancomycin · For: Thoracic Surgery; Antibiotic Prophylaxis
Sites: Hamilton, Canada; Toronto, Canada; Montreal, Canada · 4 sites in all
- Prevention of Infections in Cardiac Surgery (PICS) Prevena StudyPivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT03402945 · 4,107 participants · Start Mar 5, 2018 · Primary completion Apr 27, 2023
Drug: Cefazolin; Vancomycin · For: Surgical Site Infections
Sites: Hamilton, Canada; London, Canada
- Antibiotic Prophylaxis in Metabolic Bariatric SurgeryPivotal-lookingStatus unknown
General Committee of Teaching Hospitals and Institutes, EgyptGovernment (non-federal)
NCT06510452 · 3,352 participants (planned) · Start Oct 1, 2024 · Primary completion Dec 1, 2025
Drug: 2000 mg of Cefazolin; 500 mg of Metronidazole IV and 1 more · For: Antibiotic Reaction; Wound Infection Superficial; Wound Infection Deep and 2 more
Sites: Alexandria, Egypt; Amersfoort, Netherlands
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hypotension711
- drug ineffective679
- anaphylactic reaction659
- anaphylactic shock622
- rash600
- pyrexia518
- renal failure488
- acute kidney injury442
- off label use424
- pain417
- nausea379
- urticaria361
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 222 |
| 2005 | 210 |
| 2006 | 255 |
| 2007 | 157 |
| 2008 | 238 |
| 2009 | 224 |
| 2010 | 233 |
| 2011 | 507 |
| 2012 | 462 |
| 2013 | 268 |
| 2014 | 304 |
| 2015 | 373 |
| 2016 | 540 |
| 2017 | 510 |
| 2018 | 700 |
| 2019 | 831 |
| 2020 | 855 |
| 2021 | 805 |
| 2022 | 954 |
| 2023 | 1,008 |
| 2024 | 981 |
| 2025 | 956 |
| 2026 | 614 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cefazolin Sodium* (Cefazolin Sodium)
2024 spending
$4.4M
Beneficiaries
20,069
82,069 claims
Per beneficiary
$218
$2.07 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,102,820 |
| 2021 | $4,361,176 |
| 2022 | $4,768,566 |
| 2023 | $5,203,753 |
| 2024 | $4,371,640 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia.
Lee TC, Barina LA, Walls G, et al. · N Engl J Med 2026 · Clinical Trial, Phase IV, Comparative Study
- Cefazolin.
Quintiliani R, Nightingale CH · Ann Intern Med 1978 · Clinical Trial, Comparative Study
- Cefazolin vs. antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis.
Prosty C, Noutsios D, Lee TC, et al. · Clin Microbiol Infect 2025 · Systematic Review, Meta-Analysis
- Trial of Vancomycin and Cefazolin as Surgical Prophylaxis in Arthroplasty.
Peel TN, Astbury S, Cheng AC, et al. · N Engl J Med 2023 · Multicenter Study, Randomized Controlled Trial
- Cloxacillin versus cefazolin for meticillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-inferiority, randomised clinical trial.
Burdet C, Saïdani N, Dupieux C, et al. · Lancet 2025 · Multicenter Study, Randomized Controlled Trial
- Antibiotic resistance rates in hypervirulent Klebsiella pneumoniae strains: A systematic review and meta-analysis.
Beig M, Aghamohammad S, Majidzadeh N, et al. · J Glob Antimicrob Resist 2024 · Meta-Analysis, Systematic Review
Sponsor: Hq Spclt Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.